Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians indicate there is an unmet need for a safe and effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder (ADHD) with no risk of suicidal ideation. Such a drug has potential to earn a 25 percent patient share of the drug treated adult ADHD population, according to surveyed U.S. psychiatrists. In contrast, in Europe, such an agent would earn a markedly higher patient share of 40 percent, according to surveyed European psychiatrists.

This difference in patient share likely reflects U.S. physicians' reasonably high level of satisfaction with currently-available psychostimulants, with which they have decades of clinical experience, despite their disadvantages of abuse-liability and prescribing restrictions. Conversely, European physicians have to contend with greater prescribing restrictions, fewer treatment options, and are more averse to stimulants' risk of abuse than their U.S. counterparts. As a result, physicians would greatly welcome a safer and more effective nonstimulant alternative to Eli Lilly's Strattera as a first-line therapy for adult ADHD.

The new report entitled Attention-Deficit/Hyperactivity Disorder: Emerging Therapies Fall Short of Physicians' Expectations for Safer and More-Effective Nonstimulants finds that current and emerging drugs have not yet demonstrated substantial clinical advantages over Shire's Vyvanse, Decision Resources' 2008 clinical gold standard in the treatment of ADHD. According to interviewed physicians, none of the emerging therapies represent a major innovation in ADHD treatment or offer an overwhelmingly preferable balance of efficacy, safety and convenience compared to that of currently available psychostimulants.

"With a host of generally safe and effective stimulant products already approved for ADHD which are used to treat the majority of patients, interviewed physicians have targeted a remaining need for safer and more-effective nonstimulant alternatives that are approved for ADHD, both in children and adults," said Andrea Buurma, analyst at Decision Resources.

About the Report

Attention-Deficit/Hyperactivity Disorder: Emerging Therapies Fall Short of Physicians' Expectations for Safer and More-Effective Nonstimulants is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help clients optimize their investments in drug development. Driven by quantitative and qualitative primary research, DecisionBase 2009 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. Each report provides detailed market share, patient share and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Heather Hilty                      Elizabeth Marshall   Decision Resources                 Decision Resources, Inc.   781-296-2536                       781-296-2563   hhilty@dresources.com              emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Heather Hilty of Decision Resources, +1-781-296-2536,
hhilty@dresources.com, or Elizabeth Marshall, Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Health Plans, Employers Take Closer Look at Costs and Expand Disease Management Initiatives in Response to Diabetes Prevalence Increase

View Now